New hope for older aplastic anemia patients: drug combo may prevent dangerous transplant side effect
NCT ID NCT06752694
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 29 times
Summary
This study tests whether adding ruxolitinib to standard medications can prevent graft-versus-host disease (GVHD) in older adults with aplastic anemia who receive a stem cell transplant. GVHD occurs when donor cells attack the patient's body. The trial enrolls about 20 people aged 40 and older (or younger adults with high health risks) and aims to reduce severe GVHD while improving transplant safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.